Prometheus Laboratories Inc.

73 articles with Prometheus Laboratories Inc.

• Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin&#0174 (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma

  5/9/2013

• Prometheus Laboratories Inc. Release: New Data Support Use of PROMETHEUS&#0174 Anser&#0153 IFX Assay in Managing Infliximab Treatment Failure Among Inflammatory Bowel Disease Patients

  10/22/2012

• Prometheus Laboratories Inc. Launches New Monitoring Test to Help Guide Inflammatory Bowel Disease Management

  8/1/2012

• Clinipace Inc. Selected to Manage Prometheus Laboratories Inc. Oncology Program

  7/17/2012

• New Data Support Role of Prometheus Laboratories Inc.' Novel Assay in Optimizing IBD Treatment Management

  5/23/2012

• Supreme Court Throws Out Prometheus Laboratories Inc. Patent in Blood Test Dispute, Deals Blow to Biotechs

  3/21/2012

• Prometheus Laboratories Inc. Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company

  2/7/2012

• Prometheus Laboratories Inc. Announces New Chief Commercial Officer

  2/3/2012

• Prometheus Laboratories Inc. Announces New Chief Medical Officer

  11/14/2011

• Prometheus Laboratories Inc. Launches Next Generation IBD Diagnostic Test

  10/24/2011

• Prometheus Laboratories Inc. and the Medco Research Institute to Evaluate the Use of Prometheus Laboratories Inc.' Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients

  8/15/2011

• Prometheus Laboratories Inc. Announces Agreement to be Acquired by Nestle Health Science

  5/24/2011

• Prometheus Laboratories Inc. Obtains Exclusive US Commercialization Rights for RENCAREX(R) from Wilex AG; Wilex to Receive $19 Million Upfront

  5/2/2011

• Prometheus Laboratories Inc. Highlights Record Performance in 2010

  3/1/2011

• Prometheus Laboratories Inc. Receives New York State Approval for PROMETHEUS(R) Crohn's Prognostic, the First Serogenetic Test to Predict Risk of Complications From Crohn's Disease

  2/23/2011

• Prometheus Laboratories Inc. and University of California, Los Angeles (UCLA) Sign Agreement to Validate Biological Markers of Mucosal Healing in IBD

  12/10/2010

• Prometheus Laboratories Inc. and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis

  12/9/2010

• Prometheus Laboratories Inc. Extends Distribution Agreement for ENTOCORT(R) EC (budesonide) Capsules with AstraZeneca LP

  12/1/2010

• Rosetta Genomics Ltd. Settles Arbitration With Prometheus Laboratories Inc., Regains U.S. Rights to microRNA-Based Cancer Diagnostic Tests

  11/23/2010

• Prometheus Laboratories Inc. and Tarrot - a Business Unit of Cedars-Sinai Medical Center Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohn's Disease

  9/16/2010